Catalyst
Slingshot members are tracking this event:
Novo Nordisk (NVO) Expects to Release Data from SWITCH-1 Trial Evaluating Tresiba in Type 1 Diabetes Patients in Q1 2016
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| NVO |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 23, 2016
Occurred Source:
http://www.novonordisk.com/content/Denmark/HQ/www-novonordisk-com/en_gb/home/media/news-details.1988404.html
Related Projects
- Understanding the potential of Novo Nordisk's (NVO) Tresiba in treatment of type 2 diabetes NVO Execute By: Feb 05, 2016
Related Keywords
Switch-1, Tresiba, Insulin Glargine, Companion Trial, Type 2 Diabetes, Hypoglycemic Events
